ArticleEuropean journal of radiology open2026
A biology-informed radiomics model for prognostication of hepatocellular carcinoma based on AKR1B10 expression.
Article in European journal of radiology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Current radiomic models for hepatocellular carcinoma (HCC) prognosis rely on direct correlations between imaging features and clinical outcomes, resulting in limited biological interpretability and restricted clinical applicability. This study explores a novel biology-driven radiomic strategy focusing on AKR1B10. AKR1B10 is a functionally established molecular driver of HCC progression, and the study aims to develop an interpretable prediction model bridging imaging phenotypes and underlying tumor biology. Methods: We analyzed multi-institutional data from The Cancer Genome Atlas (TCGA) and The Cancer Imaging Archive (TCIA). After confirming the prognostic significance of AKR1B10 expression through survival and enrichment analyses, we developed a radiomics model using a cohort of 34 patients with matched computed tomography (CT) images and genomic data. Tumor and peritumoral regions were segmented, and 107 radiomic features were extracted. Feature selection was performed using maximum-relevance-minimum-redundancy (mRMR) and recursive feature elimination (RFE) algorithms, with subsequent model building via logistic regression. The model was evaluated using ROC analysis, calibration curves, and decision curve analysis. Finally, we constructed a prognostic nomogram integrating the radiomics signature with clinical variables. Results: AKR1B10 overexpression was significantly associated with poor overall survival (HR = 2.187, 95 % CI: 1.385-3.454, P < 0.001) and characteristic activation of oncogenic pathways. The radiomics model demonstrated strong performance in predicting AKR1B10 status (AUC = 0.83, 95 % CI: 0.69-0.97), with significant difference in rad-scores between AKR1B10 high- and low-expression groups (P < 0.001). The integrated nomogram showed excellent predictive accuracy for 3-year survival (AUC = 0.85) and provided clinical net benefit across threshold probabilities. Conclusions: The biology-informed radiomics model based on AKR1B10 expression demonstrates strong prognostic performance in hepatocellular carcinoma. By directly linking imaging phenotypes to a key molecular driver of HCC, this approach provides a clinically applicable and biologically interpretable tool for pre-operative risk prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.